San Diego, CA (PressExposure) November 27, 2013 -- Scott R. Pancoast, President and Chief Executive Officer of Lpath will present on "The Wet-AMD Market Beyond the Anti-VEGFs" at GTC's 6th Annual Ocular Diseases & Drug Discovery Conference held on March 20-21, 2014 in San Diego, CA.
The Wet-AMD market has had a short but fascinating history. Macugen, Lucentis, Avastin, and Eylea each represent a compelling chapter of this history, with Ophthotech hoping to add to the drama. But these compounds are all variations of the VEGF-inhibitor theme, yet 10-20% of patients are either non-responders or sub-responders to these drugs. This leaves wide open the doors to a second-line therapy...for those sub-responding patients, who face a decline of visual acuity eventually leading to blindness. Lpath, Inc. is currently testing an anti-S1P antibody called iSONEPâ¢ in a Phase 2 randomized, double-blind, well-controlled study of 160 sub-responding Wet-AMD patients. If successful, the path to approval as second-line therapy is straightforward. In addition, iSONEP will likely be studied in treatment-naÃ¯ve patients in a follow-on Phase 2b study, which would set the stage for pivotal trials for a first-line label, either as monotherapy or in combination with the VEGF-inhibitors.
Scott Pancoast has been President & CEO of Lpath since 2005 and has served as a board member since 1999. San Diego-based Lpath (NASDAQ: LPTN) is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2â¢ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which--iSONEPâ¢ for wet AMD and ASONEPâ¢ for cancer--are currently being investigated in Phase 2 trials. The third candidate is an anti-LPA antibody that holds promise in neuropathic pain and neurotrauma.
From 1994 to 2004, he was managing partner of Western States Investment Corporation, a private San Diego venture capital fund with about $100 million under management. During that time, he was CEO or interim CEO for six start-up companies and served on the board of directors for over 15 companies, including three public ones. Prior to joining WSIC, he started and ran the Midwest division of a $300 million (in revenues) publicly traded chemical manufacturer/distributor, where he was also a board member. He also served as the Chairman of the San Diego Venture Group during the late 1990s.
Mr. Pancoast earned a bachelors degree in economics (summa cum laude) from the University of Virginia, and an MBA (with honors) from the Harvard Business School.
The Ocular Diseases & Drug Discovery Conference continues to promote the discovery of ocular disease by offering presentations on novel and innovative therapeutics in ocular drug development and discovery. The conference brings together leading scientists, researchers and experts to discuss and collaborate on the latest research and development, safety assessment, regulatory issues and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases.
For more information, please visit http://www.gtcbio.com/ocular